Adult Malignant Glioma Therapeutics Market

Adult Malignant Glioma Therapeutics Market (Type - Glioblastoma Multiforme, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma, Anaplastic Oligoastrocytoma; Therapy - Chemotherapy, Targeted Drug Therapy, Radiation Therapy) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2018 - 2026

Adult Malignant Glioma Therapeutics Market – Snapshot

Gliomas account for more than 70% of all primary brain tumors. Glioblastoma is the most common (65%) and most malignant type of glioma. The global adult malignant glioma therapeutics market is characterized by an unmet medical need of improving survival rates. The market is witnessing rapid increase in novel pipeline drug candidates from major as well as emerging market players, supported by government policies to speed up the process of orphan drug approval. Hence, the global adult malignant glioma therapeutics market was valued at US$ 1.3 Bn in 2017 and is projected to expand at a significant CAGR of 9.2% from 2018 to 2026.

Glioblastoma multiforme (GBM) is among the most difficult of tumors to treat, and despite all efforts, median overall survival remains at approximately 12 months. Malignant gliomas are included in the category of rare diseases, and the orphan drug status is granted for the drug candidates in the pipeline. The designation for orphan drug allows manufacturers to qualify for various incentives, including tax credits for qualified clinical trials along with seven years of market exclusivity upon regulatory approval. Moreover, expedited drug discovery process due to advent of high throughput technology and TCGA, and increase in discretionary funding for cancer research have led to the rise in clinical trials against malignant gliomas. However, significant attrition rate in clinical trials and staggeringly high prices of new-generation cancer drugs are the major factors likely to restrain the global adult malignant glioma therapeutics market during the forecast period.

adult-malignant-glioma-therapeutics-market.jpg

In terms of type, the global adult malignant glioma therapeutics market has been classified into glioblastoma multiforme, anaplastic astrocytoma, anaplastic oligodendroglioma, anaplastic oligoastrocytoma, and others. Glioblastoma multiforme, which accounts for 12% to 15% of all intracranial tumors and 50% to 60% of all astrocytic tumors, is likely to be the most attractive segment during the forecast period, followed by anaplastic astrocytoma. Strong research and development focus of manufacturers, presence of significant patient population driving demand for effective therapeutics to improve the overall survival rate, and rapidly increasing pipeline of innovative novel drugs are attributed to the high growth of the segment. Based on therapy, the global market has been divided into chemotherapy, targeted drug therapy, and radiation drug therapy. The chemotherapy segment has been categorized into temozolomide, bevacizumab, carmustine, and others. The targeted drug therapy segment has been segmented into EGFR inhibitors, other monoclonal antibodies, and others. The market is characterized by a unique mix of patent expirations in the chemotherapy segment and rise in new patent approvals for targeted drug therapies. Loss of market exclusivity post patent expiration and reduction in branded drug prices due to competition from generic brands are likely to result in stagnant growth rate of the chemotherapy segment compared to targeted drug therapy. The targeted drug therapy segment is likely to dominate the global adult malignant glioma therapeutics market during the forecast period. This is because the segment comprises a promising pipeline covering diverse novel techniques such as gene therapy, nucleic acid therapies, lytic viruses, stem cells, nanoparticles, and others which are able to cross the blood brain barrier and target novel inhibition points rather than focusing on the inhibition of blood vessel formation.

In terms of region, the global adult malignant glioma therapeutics market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America dominated the global market in 2017, accounting for over 37% share in terms of revenue. Europe was another major market for adult malignant glioma therapeutics in 2017. Technological advancement is a major driver of the market in North America and Europe. However, growth of the market in the near future is likely to depend on the combined prospects in technology and opportunity in the developing countries in Asia such as China, Japan, India, and South Korea. The market in Asia Pacific is anticipated to register an above average growth rate during the forecast period owing to relatively high patient population demanding affordable care and improvement in health care infrastructure in rapidly developing countries that aid the early diagnosis of malignant gliomas.

Major players operating in the global adult malignant glioma therapeutics market include Merck & Co., Inc., F. Hoffmann-La Roche Ltd., Arbor Pharmaceuticals, Pfizer, Inc., AbbVie, Inc., Amgen, Inc., Bristol-Myers Squibb Company, Sun Pharmaceuticals Ltd., Teva Pharmaceutical Industries Limited, and Emcure Pharmaceuticals Limited.

The global adult malignant glioma therapeutics market has been segmented as follows:

Type

  • Glioblastoma Multiforme
  • Anaplastic Astrocytoma
  • Anaplastic Oligodendroglioma
  • Anaplastic Oligoastrocytoma
  • Others

Therapy

  • Chemotherapy
    • Temozolomide
    • Bevacizumab
    • Carmustine
    • Others
  • Targeted Drug Therapy
    • EGFR Inhibitors
    • Other Monoclonal Antibodies
    • Others
  • Radiation Therapy

Region

  • North America
    • U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia & New Zealand
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC Countries
    • South Africa
    • Rest of Middle East & Africa

    1. Preface
         1.1. Market Definition and Scope
         1.2. Market Segmentation
         1.3. Key Research Objectives
         1.4. Research Highlights

    2. Assumptions and Research Methodology

    3. Executive Summary: Global Adult Malignant Glioma Therapeutics Market

    4. Market Overview
         4.1. Introduction
                4.1.1. Market Definition
                4.1.2. Industry Evolution / Developments
         4.2. Overview
         4.3. Market Dynamics by region
                4.3.1. Drivers
                4.3.2. Restraints
                4.3.3. Opportunities
         4.4. Global Adult Malignant Glioma Therapeutics Market Analysis and Forecast, 2016–2026
                4.4.1. Market Revenue Projections (US$ Mn)
         4.5. Porter’s Five Force Analysis, by Region

    5. Market Outlook
         5.1. Adult Malignant Glioma Disease Overview
                5.1.1 Glioblastoma Multiforme
                5.1.2. Anaplastic Astrocytoma
                5.1.3. Anaplastic Oligodendroglioma
                5.1.4. Anaplastic Oligoastrocytoma
                5.1.5. Others
         5.2. Pipeline Analysis
                5.2.1. Phase III & IV Drugs Market Forecast
                5.2.1. Phase I & II Drug Candidates Comparative Analysis
         5.3. Porter’s Five Force Analysis, by Region
         5.4. Epidemiology of Glioma
                5.4.1. Prevalence, by Country
                5.4.2. Prevalence, by Type of Glioma
                5.4.3. Incidence Rate, by Country
                5.4.4. Incidence Rate, by Type of Glioma
         5.5. Disease Burden by Key Regions / Country
                5.5.1. North America
                5.5.2. Europe
                5.5.3. Asia Pacific
                5.5.4. Rest of the World
         5.6. SWOT Analysis, by Key Therapies
         5.7. Regulatory Scenario, by Key Region / Country
         5.8. Reimbursement Scenario, by Key Region / Country
         5.9. Imaging Technologies Landscape in Glioma Analysis
         5.10. Key Market Trends, by Region

    6. Global Adult Malignant Glioma Therapeutics Market Analysis and Forecast, by Type
         6.1. Introduction & Definition
         6.2. Key Findings / Developments
         6.3. Global Adult Malignant Glioma Therapeutics Market Value Forecast, by Type, 2016– 2026
                6.3.1. Glioblastoma Multiforme
                6.3.2. Anaplastic Astrocytoma
                6.3.3. Anaplastic Oligodendroglioma
                6.3.4. Anaplastic Oligoastrocytoma
                6.3.5. Others
         6.4. Global Adult Malignant Glioma Therapeutics Market Attractiveness, by Type

    7. Global Adult Malignant Glioma Therapeutics Market Analysis and Forecast, by Therapy
         7.1. Introduction & Definition
         7.2. Key Findings / Developments
         7.3. Global Adult Malignant Glioma Therapeutics Market Value Forecast, by Therapy, 2016–2026
                7.3.1. Chemotherapy
                         7.3.1.1. Temozolomide
                         7.3.1.2. Bevacizumab
                         7.3.1.3. Carmustine
                         7.3.1.4. Others
                7.3.2. Targeted Drug Therapy
                         7.3.2.1. Epidermal Growth Factor Receptor (EGFR) Inhibitors
                         7.3.2.2. Other Monoclonal Antibodies
                         7.3.2.3. Others
                7.3.3. Radiation Therapy
         7.4. Global Adult Malignant Glioma Therapeutics Market Attractiveness, by Therapy

    8. Global Adult Malignant Glioma Therapeutics Market Analysis and Forecast, by Region
         8.1. Key Findings
         8.2. Global Adult Malignant Glioma Therapeutics Market Value Forecast, by Region
                8.2.1. North America
                8.2.2. Europe
                8.2.3. Asia Pacific
                8.2.4. Latin America
                8.2.5. Middle East & Africa
         8.3. Market Attractiveness, by Region

    9. North America Adult Malignant Glioma Therapeutics Market Analysis and Forecast
         9.1. Introduction
                9.1.1. Key Findings
         9.2. North America Adult Malignant Glioma Therapeutics Market Value Forecast, by Type, 2016–2026
                9.2.1. Glioblastoma Multiforme
                9.2.2. Anaplastic Astrocytoma
                9.2.3. Anaplastic Oligodendroglioma
                9.2.4. Anaplastic Oligoastrocytoma
                9.2.5. Others
         9.3. North America Adult Malignant Glioma Therapeutics Market Value Forecast, by Therapy, 2016–2026
                9.3.1. Chemotherapy
                         9.3.1.1. Temozolomide
                         9.3.1.2. Bevacizumab
                         9.3.1.3. Carmustine
                         9.3.1.4. Others
                9.3.2. Targeted Drug Therapy
                         9.3.2.1. Epidermal Growth Factor Receptor (EGFR) Inhibitors
                         9.3.2.2. Other Monoclonal Antibodies
                         9.3.2.3. Others
                9.3.3. Radiation Therapy
         9.4. North America Adult Malignant Glioma Therapeutics Market Value Forecast, by Country, 2016–2026
                9.4.1. U.S.
                9.4.2. Canada
         9.5. Market Attractiveness Analysis
                9.5.1. By Type
                9.5.2. By Therapy
                9.5.3. By Country

    10. Europe Adult Malignant Glioma Therapeutics Market Analysis and Forecast
         10.1. Introduction
                10.1.1. Key Findings
         10.2. Europe Adult Malignant Glioma Therapeutics Market Value Forecast, by Type, 2016–2026
                10.2.1. Glioblastoma Multiforme
                10.2.2. Anaplastic Astrocytoma
                10.2.3. Anaplastic Oligodendroglioma
                10.2.4. Anaplastic Oligoastrocytoma
                10.2.5. Others
         10.3. Europe Adult Malignant Glioma Therapeutics Market Value Forecast, by Therapy, 2016–2026
                10.3.1. Chemotherapy
                         10.3.1.1. Temozolomide
                         10.3.1.2. Bevacizumab
                         10.3.1.3. Carmustine
                         10.3.1.4. Others
                10.3.2. Targeted Drug Therapy
                         10.3.2.1. Epidermal Growth Factor Receptor (EGFR) Inhibitors
                         10.3.2.2. Other Monoclonal Antibodies
                         10.3.2.3. Others
                10.3.3. Radiation Therapy
         10.4. Europe Adult Malignant Glioma Therapeutics Market Value Forecast, by Country/Sub-region, 2016–2026
                10.4.1. Germany
                10.4.2. U.K.
                10.4.3. France
                10.4.4. Spain
                10.4.5. Italy
                10.4.6. Rest of Europe
         10.5. Europe Adult Malignant Glioma Therapeutics Market Attractiveness Analysis
                10.5.1. By Type
                10.5.2. By Therapy
                10.5.3. By Country/Sub-region

    11. Asia Pacific Adult Malignant Glioma Therapeutics Market Analysis and Forecast
         11.1.Introduction
                11.1.1. Key Findings
         11.2. Asia Pacific Adult Malignant Glioma Therapeutics Market Value Forecast, by Type, 2016–2026
                11.2.1. Glioblastoma Multiforme
                11.2.2. Anaplastic Astrocytoma
                11.2.3. Anaplastic Oligodendroglioma
                11.2.4. Anaplastic Oligoastrocytoma
                11.2.5. Others
         11.3. Asia Pacific Adult Malignant Glioma Therapeutics Market Value Forecast, by Therapy, 2016–2026
                11.3.1. Chemotherapy
                         11.3.1.1. Temozolomide
                         11.3.1.2. Bevacizumab
                         11.3.1.3. Carmustine
                         11.3.1.4. Others
                11.3.2. Targeted Drug Therapy
                         11.3.2.1. Epidermal Growth Factor Receptor (EGFR) Inhibitors
                         11.3.2.2. Other Monoclonal Antibodies
                         11.3.2.3. Others
                11.3.3. Radiation Therapy
         11.4. Asia Pacific Adult Malignant Glioma Therapeutics Market Value Forecast, by Country/Sub-region, 2016–2026
                11.4.1. China
                11.4.2. Japan
                11.4.3. India
                11.4.4. Rest of Asia Pacific
         11.5. Asia Pacific Adult Malignant Glioma Therapeutics Market Attractiveness Analysis
                11.5.1. By Type
                11.5.2. By Therapy
                11.5.3. By Country/Sub-region

    12. Latin America Adult Malignant Glioma Therapeutics Market Analysis and Forecast
         12.1.Introduction
                12.1.1. Key Findings
         12.2. Latin America Adult Malignant Glioma Therapeutics Market Value Forecast, by Type, 2016–2026
                12.2.1. Glioblastoma Multiforme
                12.2.2. Anaplastic Astrocytoma
                12.2.3. Anaplastic Oligodendroglioma
                12.2.4. Anaplastic Oligoastrocytoma
                12.2.5. Others
         12.3. Asia Pacific Adult Malignant Glioma Therapeutics Market Value Forecast, by Therapy, 2016–2026
                12.3.1. Chemotherapy
                         12.3.1.1. Temozolomide
                         12.3.1.2. Bevacizumab
                         12.3.1.3. Carmustine
                         12.3.1.4. Others
                12.3.2. Targeted Drug Therapy
                         12.3.2.1. Epidermal Growth Factor Receptor (EGFR) Inhibitors
                         12.3.2.2. Other Monoclonal Antibodies
                         12.3.2.3. Others
                12.3.3. Radiation Therapy
         12.4. Asia Pacific Adult Malignant Glioma Therapeutics Market Value Forecast, by Country/Sub-region, 2016–2026
                12.4.1. Brazil
                12.4.2. Mexico
                12.4.3. Rest of Latin America
         12.5. Asia Pacific Adult Malignant Glioma Therapeutics Market Attractiveness Analysis
                12.5.1. By Type
                12.5.2. By Therapy
                12.5.3. By Country/Sub-region

    13. Middle East & Africa Adult Malignant Glioma Therapeutics Market Analysis and Forecast
         13.1.Introduction
                13.1.1. Key Findings
         13.2. MEA Adult Malignant Glioma Therapeutics Market Value Forecast, by Type, 2016–2026
                13.2.1. Glioblastoma Multiforme
                13.2.2. Anaplastic Astrocytoma
                13.2.3. Anaplastic Oligodendroglioma
                13.2.4. Anaplastic Oligoastrocytoma
                13.2.5. Others
         13.3. MEA Adult Malignant Glioma Therapeutics Market Value Forecast, by Therapy, 2016–2026
                13.3.1. Chemotherapy
                         13.3.1.1. Temozolomide
                         13.3.1.2. Bevacizumab
                         13.3.1.3. Carmustine
                         13.3.1.4. Others
                13.3.2. Targeted Drug Therapy
                         13.3.2.1. Epidermal Growth Factor Receptor (EGFR) Inhibitors
                         13.3.2.2. Other Monoclonal Antibodies
                         13.3.2.3. Others
                13.3.3. Radiation Therapy
         13.4. MEA Adult Malignant Glioma Therapeutics Market Value Forecast, by Country/Sub-region, 2016–2026
                13.4.1. GCC Countries
                13.4.2. South Africa
                13.4.3. Rest of Middle East & Africa
         13.5. MEA Adult Malignant Glioma Therapeutics Market Attractiveness Analysis
                13.5.1. By Type
                13.5.2. By Therapy
                13.5.3. By Country/Sub-region

    14. Competition Landscape
         14.1.Market Player - Competition Matrix (By Tier and Size of companies)
         14.2.Market Share Analysis, by Company (2017)
         14.3.Market Footprint Analysis
         14.4. Competitive Business Strategies
         14.5. Company Profiles
                14.5.1. Merck & Co., Inc.
                         14.5.1.1. Company Overview (HQ, Business Segments, Employee Strength)
                         14.5.1.2. Product Portfolio
                         14.5.1.3. SWOT Analysis
                         14.5.1.4. Strategic Overview
                         14.5.1.5. Financial Overview
                14.5.2. F. Hoffmann-La Roche Ltd.
                         14.5.2.1. Company Overview (HQ, Business Segments, Employee Strength)
                         14.5.2.2. Product Portfolio
                         14.5.2.3. SWOT Analysis
                         14.5.2.4. Strategic Overview
                         14.5.2.5. Financial Overview
                14.5.3. Arbor Pharmaceuticals
                         14.5.3.1. Company Overview (HQ, Business Segments, Employee Strength)
                         14.5.3.2. Product Portfolio
                         14.5.3.3. SWOT Analysis
                         14.5.3.4. Strategic Overview
                         14.5.3.5. Financial Overview
                14.5.4. Pfizer, Inc.
                         14.5.4.1. Company Overview (HQ, Business Segments, Employee Strength)
                         14.5.4.2. Product Portfolio
                         14.5.4.3. SWOT Analysis
                         14.5.4.4. Strategic Overview
                         14.5.4.5. Financial Overview
                14.5.5. AbbVie, Inc.
                         14.5.5.1. Company Overview (HQ, Business Segments, Employee Strength)
                         14.5.5.2. Product Portfolio
                         14.5.5.3. SWOT Analysis
                         14.5.5.4. Strategic Overview
                         14.5.5.5. Financial Overview
                14.5.6. Amgen, Inc.
                         14.5.6.1. Company Overview (HQ, Business Segments, Employee Strength)
                         14.5.6.2. Product Portfolio
                         14.5.6.3. SWOT Analysis
                         14.5.6.4. Strategic Overview
                         14.5.6.5. Financial Overview
                14.5.7. Bristol-Myers Squibb Company
                         14.5.7.1. Company Overview (HQ, Business Segments, Employee Strength)
                         14.5.7.2. Product Portfolio
                         14.5.7.3. SWOT Analysis
                         14.5.7.4. Strategic Overview
                         14.5.7.5. Financial Overview
                14.5.8. Sun Pharmaceuticals Ltd.
                         14.5.8.1. Company Overview (HQ, Business Segments, Employee Strength)
                         14.5.8.2. Product Portfolio
                         14.5.8.3. SWOT Analysis
                         14.5.8.4. Strategic Overview
                         14.5.8.5. Financial Overview
                14.5.9. Teva Pharmaceutical Industries Limited
                         14.5.9.1. Company Overview (HQ, Business Segments, Employee Strength)
                         14.5.9.2. Product Portfolio
                         14.5.9.3. SWOT Analysis
                         14.5.9.4. Strategic Overview
                         14.5.9.5. Financial Overview
                14.5.10. Emcure Pharmaceuticals Limited
                         14.5.10.1. Company Overview (HQ, Business Segments, Employee Strength)
                         14.5.10.2. Product Portfolio
                         14.5.10.3. SWOT Analysis
                         14.5.10.4. Strategic Overview
                         14.5.10.5. Financial Overview

    List of Tables

    Table 01: Signatures and Clinical Features of Glioblastoma (GBM) Subtypes
    Table 02: Disease Burden, by Key Region/Country (1/2)
    Table 03: Disease Burden, by Key Region/Country (2/2)
    Table 04: Comparative Analysis of Orphan Drug Policies
    Table 05: Global Adult Malignant Glioma Therapeutics Market Value (US$ Mn) Forecast, by Type, 2016–2026
    Table 06: Global Adult Malignant Glioma Therapeutics Market Value (US$ Mn) Forecast, by Therapy, 2016–2026
    Table 07: Global Adult Malignant Glioma Therapeutics Market Value (US$ Mn) Forecast, by Chemotherapy, 2016–2026
    Table 08: Global Adult Malignant Glioma Therapeutics Market Value (US$ Mn) Forecast, by Targeted Drug Therapy, 2016–2026
    Table 09: Global Adult Malignant Glioma Therapeutics Market Value (US$ Mn) Forecast, by Region, 2016–2026
    Table 10: North America Adult Malignant Glioma Therapeutics Market Value (US$ Mn) Forecast, by Country, 2016–2026
    Table 11: North America Adult Malignant Glioma Therapeutics Market Value (US$ Mn) Forecast, by Type, 2016–2026
    Table 12: North America Adult Malignant Glioma Therapeutics Market Value (US$ Mn) Forecast, by Therapy, 2016–2026
    Table 13: North America Adult Malignant Glioma Therapeutics Market Value (US$ Mn) Forecast, by Chemotherapy, 2016–2026
    Table 14: North America Adult Malignant Glioma Therapeutics Market Value (US$ Mn) Forecast, by Targeted Drug Therapy, 2016–2026
    Table 15: Europe Adult Malignant Glioma Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
    Table 16: Europe Adult Malignant Glioma Therapeutics Market Value (US$ Mn) Forecast, by Type, 2016–2026
    Table 17: Europe Adult Malignant Glioma Therapeutics Market Value (US$ Mn) Forecast, by Therapy, 2016–2026
    Table 18: Europe Adult Malignant Glioma Therapeutics Market Value (US$ Mn) Forecast, by Chemotherapy, 2016–2026
    Table 19: Europe Adult Malignant Glioma Therapeutics Market Value (US$ Mn) Forecast, by Targeted Drug Therapy, 2016–2026
    Table 20: Asia Pacific Adult Malignant Glioma Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
    Table 21: Asia Pacific Adult Malignant Glioma Therapeutics Market Value (US$ Mn) Forecast, by Type, 2016–2026
    Table 22: Asia Pacific Adult Malignant Glioma Therapeutics Market Value (US$ Mn) Forecast, by Therapy, 2016–2026
    Table 23: Asia Pacific Adult Malignant Glioma Therapeutics Market Value (US$ Mn) Forecast, by Chemotherapy, 2016–2026
    Table 24: Asia Pacific Adult Malignant Glioma Therapeutics Market Value (US$ Mn) Forecast, by Targeted Drug Therapy, 2016–2026
    Table 25: Latin America Adult Malignant Glioma Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
    Table 26: Latin America Adult Malignant Glioma Therapeutics Market Value (US$ Mn) Forecast, by Type, 2016–2026
    Table 27: Latin America Adult Malignant Glioma Therapeutics Market Value (US$ Mn) Forecast, by Therapy, 2016–2026
    Table 28: Latin America Adult Malignant Glioma Therapeutics Market Value (US$ Mn) Forecast, by Chemotherapy, 2016–2026
    Table 29: Latin America Adult Malignant Glioma Therapeutics Market Value (US$ Mn) Forecast, by Targeted Drug Therapy, 2016–2026
    Table 30: Middle East & Africa Adult Malignant Glioma Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
    Table 31: Middle East & Africa Adult Malignant Glioma Therapeutics Market Value (US$ Mn) Forecast, by Type, 2016–2026
    Table 32: Middle East & Africa Adult Malignant Glioma Therapeutics Market Value (US$ Mn) Forecast, by Therapy, 2016–2026
    Table 33: Middle East & Africa Adult Malignant Glioma Therapeutics Market Value (US$ Mn) Forecast, by Chemotherapy, 2016–2026
    Table 34: Middle East & Africa Adult Malignant Glioma Therapeutics Market Value (US$ Mn) Forecast, by Targeted Drug Therapy, 2016–2026

    List of Figures

    Figure 01: Global Adult Malignant Glioma Therapeutics Market Value (US$ Mn) Forecast, 2016–2026
    Figure 02: Global Adult Malignant Glioma Therapeutics Market Value Share (%), by Type (2017)
    Figure 03: Global Adult Malignant Glioma Therapeutics Market Value Share (%), by Therapy (2017)
    Figure 04: Global Adult Malignant Glioma Therapeutics Market Value Share (%), by Region (2017)
    Figure 05: Overall Survival Time of Glioblastoma Patients, by Therapy
    Figure 06: Overall Survival Time of Glioblastoma Patients, by Age Group
    Figure 07: Glioblastoma Patients Relative Survival Rates
    Figure 08: Overall Incidence Rate of Glioma %
    Figure 09: Regulatory Approval Process - U.S.
    Figure 10: Regulatory Approval Process - Europe
    Figure 11: Regulatory Approval Process - Japan
    Figure 12: Global Adult Malignant Glioma Therapeutics Market Trends, by Region
    Figure 13: Global Adult Malignant Glioma Therapeutics Market Value Share (%), by Type, 2017 and 2026
    Figure 14: Global Adult Malignant Glioma Therapeutics Market Attractiveness, by Type, 2018–2026
    Figure 15: Global Adult Malignant Glioma Therapeutics Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Glioblastoma Multiforme, 2016–2026
    Figure 16: Global Adult Malignant Glioma Therapeutics Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Anaplastic Astrocytoma, 2016–2026
    Figure 17: Global Adult Malignant Glioma Therapeutics Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Anaplastic Oligodendroglioma, 2016–2026
    Figure 18: Global Adult Malignant Glioma Therapeutics Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Anaplastic Oligoastrocytoma, 2016–2026
    Figure 19: Global Adult Malignant Glioma Therapeutics Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Others, 2016–2026
    Figure 20: Global Adult Malignant Glioma Therapeutics Market Value Share (%), by Therapy, 2017 and 2026
    Figure 21: Global Adult Malignant Glioma Therapeutics Market Attractiveness, by Therapy, 2018–2026
    Figure 22: Global Adult Malignant Glioma Therapeutics Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Chemotherapy, 2016–2026
    Figure 23: Global Adult Malignant Glioma Therapeutics Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Targeted Therapy, 2016–2026
    Figure 24: Global Adult Malignant Glioma Therapeutics Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Radiation Therapy, 2016–2026
    Figure 25: Global Adult Malignant Glioma Therapeutics Market Value Share (%), by Region, 2017 and 2026
    Figure 26: Global Adult Malignant Glioma Therapeutics Market Attractiveness, by Region, 2018–2026
    Figure 27: North America Adult Malignant Glioma Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, 2016–2026
    Figure 28: North America Adult Malignant Glioma Therapeutics Market Value Share (%), by Country, 2017 and 2026
    Figure 29: North America Adult Malignant Glioma Therapeutics Market Attractiveness, by Country, 2018– 2026
    Figure 30: North America Adult Malignant Glioma Therapeutics Market Value Share (%), by Type, 2017 and 2026
    Figure 31: North America Adult Malignant Glioma Therapeutics Market Attractiveness, by Type, 2018–2026
    Figure 32: North America Adult Malignant Glioma Therapeutics Market Value Share (%), by Therapy, 2017 and 2026
    Figure 33: North America Adult Malignant Glioma Therapeutics Market Attractiveness, by Therapy, 2018– 2026
    Figure 34: Europe Adult Malignant Glioma Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, 2016–2026
    Figure 35: Europe Adult Malignant Glioma Therapeutics Market Value Share (%), by Country/Sub-region, 2017 and 2026
    Figure 36: Europe Adult Malignant Glioma Therapeutics Market Attractiveness, by Country/Sub-region, 2018–2026
    Figure 37: Europe Adult Malignant Glioma Therapeutics Market Value Share (%), by Type, 2017 and 2026
    Figure 38: Europe Adult Malignant Glioma Therapeutics Market Attractiveness, by Type, 2018–2026
    Figure 39: Europe Adult Malignant Glioma Therapeutics Market Value Share (%), by Therapy, 2017 and 2026
    Figure 40: Europe Adult Malignant Glioma Therapeutics Market Attractiveness, by Therapy, 2018–2026
    Figure 41: Asia Pacific Adult Malignant Glioma Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, 2016–2026
    Figure 42: Asia Pacific Adult Malignant Glioma Therapeutics Market Value Share (%), by Country/Sub- region, 2017 and 2026
    Figure 43: Asia Pacific Adult Malignant Glioma Therapeutics Market Attractiveness, by Country/Sub-region, 2018–2026
    Figure 44: Asia Pacific Adult Malignant Glioma Therapeutics Market Value Share (%), by Type 2017 and 2026
    Figure 45: Asia Pacific Adult Malignant Glioma Therapeutics Market Attractiveness, by Type, 2018–2026
    Figure 46: Asia Pacific Adult Malignant Glioma Therapeutics Market Value Share (%), by Therapy 2017 and 2026
    Figure 47: Asia Pacific Adult Malignant Glioma Therapeutics Market Attractiveness, by Therapy 2018–2026
    Figure 48: Latin America Adult Malignant Glioma Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, 2016–2026
    Figure 49: Latin America Adult Malignant Glioma Therapeutics Market Value Share (%), by Country/Sub- region, 2017 and 2026
    Figure 50: Latin America Adult Malignant Glioma Therapeutics Market Attractiveness, by Country/Sub- region, 2018–2026
    Figure 51: Latin America Adult Malignant Glioma Therapeutics Market Value Share (%), by Type, 2017 and 2026
    Figure 52: Latin America Adult Malignant Glioma Therapeutics Market Attractiveness, by Type, 2018–2026
    Figure 53: Latin America Adult Malignant Glioma Therapeutics Market Value Share (%), by Therapy, 2017 and 2026
    Figure 54: Latin America Adult Malignant Glioma Therapeutics Market Attractiveness, by Therapy, 2018– 2026
    Figure 55 Middle East & Africa Adult Malignant Glioma Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, 2016–2026
    Figure 56: Middle East & Africa Adult Malignant Glioma Therapeutics Market Value Share (%), by Country/Sub-region, 2017 and 2026
    Figure 57: Middle East & Africa Adult Malignant Glioma Therapeutics Market Attractiveness, by Country/Sub-region, 2018–2026
    Figure 58: Middle East & Africa Adult Malignant Glioma Therapeutics Market Value Share (%), by Type, 2017 and 2026
    Figure 59: Middle East & Africa Adult Malignant Glioma Therapeutics Market Attractiveness, by Type, 2018– 2026
    Figure 60: Middle East & Africa Adult Malignant Glioma Therapeutics Market Value Share (%), by Therapy, 2017 and 2026
    Figure 61: Middle East & Africa Adult Malignant Glioma Therapeutics Market Attractiveness, by Therapy, 2018–2026
    Figure 62: Global Adult Malignant Glioma Therapeutics Market Share, by Company, 2017
    Figure 63: AbbVie, Inc. Revenue (US$ Bn) and Y-o-Y Growth (%), 2014–2017
    Figure 64: AbbVie, Inc. Breakdown of Net Sales, by Region, 2017
    Figure 65: AbbVie, Inc. Breakdown of Net Sales, by Drug, 2017
    Figure 66: AbbVie, Inc. Research and Development Cost (US$ Mn), 2015–2017
    Figure 67: Merck & Co., Inc. Revenue (US$ Mn) & Y-o-Y Growth (%), 2015–2017
    Figure 68: Merck & Co., Inc. Breakdown of Net Sales, by Region, 2017
    Figure 69: Merck & Co., Inc. Breakdown of Net Sales, by Business Segment, 2017
    Figure 70: Merck & Co., Inc. Research & Development Cost, 2015–2017 (US$ Bn)
    Figure 71: Pfizer Inc. Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2017
    Figure 72: Pfizer Inc. R&D Expenses (US$ Mn), 2014–2017
    Figure 73: F. Hoffmann-La Roche Ltd Revenue (US$ Mn) & Y-o-Y Growth (%), 2014–2017
    Figure 74: F. Hoffmann-La Roche Ltd Breakdown of Net Sales, by Region, 2017
    Figure 75: F. Hoffmann-La Roche Ltd Breakdown of Net Sales, by Business Segment, 2017
    Figure 76: F. Hoffmann-La Roche Ltd Research & Development Cost, 2015–2017 (US$ Mn)
    Figure 77: Bristol-Myers Squibb Company Revenue (US$ Bn) & Y-o-Y Growth (%), 2014–2017
    Figure 78: Bristol-Myers Squibb Company Breakdown of Net Sales (%), by Region, 2017
    Figure 79: Bristol-Myers Squibb Company Breakdown of Net Sales, by Product Segment, 2017
    Figure 80: Bristol-Myers Squibb Company Research & Development Cost, 2015–2017 (US$ Mn)
    Figure 81: Amgen, Inc. Revenue (US$ Bn) and Y-o-Y Growth (%), 2014–2017
    Figure 82: Amgen, Inc. Breakdown of Net Sales, by Region, 2017
    Figure 83: Amgen, Inc. Breakdown of Net Sales, by Type of Sale, 2017
    Figure 84: Amgen, Inc. Research and Development Cost (US$ Mn), 2015–2017
    Figure 85: Sun Pharmaceuticals Ltd. Revenue (US$ Mn) and Y-o-Y Growth (%), 2013–2016
    Figure 86: Sun Pharmaceuticals Ltd. Breakdown of Net Sales, by Region, 2017
    Figure 87: Sun Pharmaceuticals Ltd. Breakdown of Net Sales, by Product Segment, 2017
    Figure 88: Sun Pharmaceuticals Ltd. Research & Development Cost (US$ Mn), 2015–2017
    Figure 89: Teva Pharmaceutical Industries Limited Revenue (US$ Bn) and Y-o-Y Growth (%), 2014–2017
    Figure 90: Teva Pharmaceutical Industries Limited Breakdown of Net Sales, by Region, 2017
    Figure 91: Teva Pharmaceutical Industries Limited Breakdown of Net Sales, by Business Segment, 2017
    Figure 92: Teva Pharmaceutical Industries Limited Research and Development Cost (US$ Mn), 2015–2017

Copyright © Transparency Market Research, Inc. All Rights reserved